A case of metastatic Xp11.2 translocation renal cell carcinoma successfully managed by cytoreductive nephrectomy followed by axitinib therapy

Nishimura,Koichi; Takagi,Toshio; Toda,Naohiro; Yamamoto,Tomoko; Kondo,Tsunenori; Ishida,Hideki; Nagashima,Yoji; Tanabe,Kazunari

doi:10.3892/mco.2017.1142

A case of metastatic Xp11.2 translocation renal cell carcinoma successfully managed by cytoreductive nephrectomy followed by axitinib therapy

Authors:
- Koichi Nishimura
- Toshio Takagi
- Naohiro Toda
- Tomoko Yamamoto
- Tsunenori Kondo
- Hideki Ishida
- Yoji Nagashima
- Kazunari Tanabe
View Affiliations

Affiliations: Department of Urology, Tokyo Women's Medical University, Tokyo 162-8666, Japan, Department of Surgical Pathology, Tokyo Women's Medical University, Tokyo 162-8666, Japan
Published online on: January 31, 2017 https://doi.org/10.3892/mco.2017.1142
Pages: 362-364

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Targeted medications for metastatic adult Xp11.2 translocation renal cell carcinoma (RCC) remain to be identified. We herein report a case of metastatic Xp11.2 translocation RCC controlled with cytoreductive nephrectomy (CN) and axitinib therapy. A 57-year-old woman complained of fatigue and low back pain. Imaging studies revealed a right renal tumor, with multiple lung and mediastinal lymph node metastases. Although the patient received 10 mg axitinib therapy for 5 months at the hospital she was initially admitted to, the size of the primary and metastatic lesions was not reduced. Thus, she was referred to the Tokyo Women's Medical University Hospital (Tokyo, Japan) for further treatment, where she underwent CN. On macroscopic examination, almost the entire kidney was replaced by a yellowish brown tumor >80 mm in diameter. Immunohistochemical examination confirmed the diagnosis of Xp11.2 translocation RCC. One month after surgery, axitinib therapy was resumed and the size of the metastatic lesions gradually decreased. These findings suggest that axitinib therapy is effective for adult Xp11.2 translocation RCC.

View Figures

View References

1	Armah HB and Parwani AV: Xp11.2 translocation renal cell carcinoma. Arch Pathol Lab Med. 134:124–129. 2010.PubMed/NCBI
2	Komai Y, Fujiwara M, Fujii Y, Mukai H, Yonese J, Kawakami S, Yamamoto S, Migita T, Ishikawa Y, Kurata M, et al: Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res. 15:1170–1176. 2009. View Article : Google Scholar : PubMed/NCBI
3	Argani P, Olgac S, Tickoo SK, Goldfischer M, Moch H, Chan DY, Eble JN, Bonsib SM, Jimeno M, Lloreta J, et al: Xp11 translocation renal cell carcinoma in adults: Expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 31:1149–1160. 2007. View Article : Google Scholar : PubMed/NCBI
4	Rais-Bahrami S, Drabick JJ, De Marzo AM, Hicks J, Ho C, Caroe AE and Argani P: Xp11 translocation renal cell carcinoma: Delayed but massive and lethal metastases of a chemotherapy-associated secondary malignancy. Urology. 70:178.e3–178.e6. 2007. View Article : Google Scholar
5	Armah HB and Parwani AV: Renal cell carcinoma in a 33-year-old male with an unusual morphology and an aggressive clinical course: Possible Xp11.2 translocation. Pathology. 40:306–308. 2008. View Article : Google Scholar : PubMed/NCBI
6	Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, Saito T, Laé M, Fisher DE and Ladanyi M: TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 67:919–929. 2007. View Article : Google Scholar : PubMed/NCBI
7	Camparo P, Vasiliu V, Molinie V, Couturier J, Dykema KJ, Petillo D, Furge KA, Comperat EM, Lae M, Bouvier R, et al: Renal translocation carcinomas: Clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol. 32:656–670. 2008. View Article : Google Scholar : PubMed/NCBI
8	Motzer RJ, Bacik J, Murphy BA, Russo P and Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 20:289–296. 2002. View Article : Google Scholar : PubMed/NCBI
9	Choueiri TK, Lim ZD, Hirsch MS, Tamboli P, Jonasch E, McDermott DF, Dal Cin P, Corn P, Vaishampayan U, Heng DY, et al: Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. 116:5219–5225. 2010. View Article : Google Scholar : PubMed/NCBI
10	Malouf GG, Camparo P, Oudard S, Schleiermacher G, Theodore C, Rustine A, Dutcher J, Billemont B, Rixe O, Bompas E, et al: Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): A report from the Juvenile RCC Network. Ann Oncol. 21:1834–1838. 2010. View Article : Google Scholar : PubMed/NCBI
11	Sudour-Bonnange H, Leroy X, Chauvet MP, Classe M, Robin PM and Leblond P: Cutaneous metastases during an aggressive course of Xp11.2 translocation renal cell carcinoma in a teenager. Pediatr Blood Cancer. 61:1698–1700. 2014. View Article : Google Scholar : PubMed/NCBI
12	Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N and Crawford ED: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 345:1655–1659. 2001. View Article : Google Scholar : PubMed/NCBI
13	Mickisch GH, Garin A, van Poppel H, de Prijck L and Sylvester R: European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet. 358:966–970. 2001. View Article : Google Scholar : PubMed/NCBI
14	Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI and Heng DY: The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 185:60–66. 2011. View Article : Google Scholar : PubMed/NCBI
15	Conti SL, Thomas IC, Hagedorn JC, Chung BI, Chertow GM, Wagner TH, Brooks JD, Srinivas S and Leppert JT: Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer. 134:2245–2252. 2014. View Article : Google Scholar : PubMed/NCBI
16	Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol. 27:5794–5799. 2009. View Article : Google Scholar : PubMed/NCBI
17	Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, et al: Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 66:704–710. 2014. View Article : Google Scholar : PubMed/NCBI